MX2022015489A - Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus. - Google Patents

Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.

Info

Publication number
MX2022015489A
MX2022015489A MX2022015489A MX2022015489A MX2022015489A MX 2022015489 A MX2022015489 A MX 2022015489A MX 2022015489 A MX2022015489 A MX 2022015489A MX 2022015489 A MX2022015489 A MX 2022015489A MX 2022015489 A MX2022015489 A MX 2022015489A
Authority
MX
Mexico
Prior art keywords
mva
vaccinia virus
modified vaccinia
virus ankara
recombinant modified
Prior art date
Application number
MX2022015489A
Other languages
English (en)
Inventor
Robin Steigerwald
Jürgen Hausmann
Matthias Habjan
Echeverz Jose Medina
Stephan Rambichler
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2022015489A publication Critical patent/MX2022015489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a un virus vaccinia modificado de Ankara (MVA) recombinante que codifica una proteína espicular (S) o una parte de esta, tal como un dominio de unión al receptor (RBD) y secuencias antigénicas adicionales derivadas de otras proteínas del coronavirus-2 del síndrome respiratorio agudo severo (SARS-CoV-2), el agente causal de la enfermedad por coronavirus 19 (COVID-19).
MX2022015489A 2020-06-10 2021-06-10 Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus. MX2022015489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179347 2020-06-10
PCT/EP2021/065726 WO2021250219A1 (en) 2020-06-10 2021-06-10 A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease

Publications (1)

Publication Number Publication Date
MX2022015489A true MX2022015489A (es) 2023-03-22

Family

ID=71092306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015489A MX2022015489A (es) 2020-06-10 2021-06-10 Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.

Country Status (9)

Country Link
US (1) US20230233670A1 (es)
EP (1) EP4164682A1 (es)
JP (1) JP2023528984A (es)
KR (1) KR20230022206A (es)
AU (1) AU2021290177A1 (es)
CA (1) CA3181431A1 (es)
IL (1) IL298834A (es)
MX (1) MX2022015489A (es)
WO (1) WO2021250219A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
LT2912183T (lt) 2012-10-28 2020-07-27 Bavarian Nordic A/S Pr13.5 promotorius, skirtas stipriam t-lastelių ir antikūnų atsakui sukelti
JP2017530114A (ja) * 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
JP2023513611A (ja) * 2020-02-14 2023-03-31 ゲオバックス インコーポレイテッド Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Also Published As

Publication number Publication date
WO2021250219A1 (en) 2021-12-16
CA3181431A1 (en) 2021-12-16
KR20230022206A (ko) 2023-02-14
US20230233670A1 (en) 2023-07-27
IL298834A (en) 2023-02-01
JP2023528984A (ja) 2023-07-06
AU2021290177A1 (en) 2023-01-19
EP4164682A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CO2020002283A2 (es) Métodos de terapia génica del factor viii (fviii)
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
MX2022001028A (es) Vacuna de la fiebre porcina africana.
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
UY39396A (es) Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2
EP4205761A4 (en) NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING THE SAME, VECTOR COMPRISING THE POLYNUCLEOTIDE, AND VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION, COMPRISING THE VECTOR
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
PH12020551944A1 (en) Reverse peptide vaccine
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
BRPI0512393A (pt) vacinação de jaritataca e/ou mangusto contra raiva
WO2023150638A3 (en) Omicron coronavirus vaccine constructs and methods of making and using same
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
WO2023031306A3 (en) New coronavirus vaccine and method for designing and obtaining a virus vaccine
EA202192936A1 (ru) Варианты капсидов aav для доставки в стекловидное тело
BR112022018822A2 (pt) Proteínas de pontos de coronavírus haptenizados